MLchartDataset catalogue

Inrebic

Term · Oncology and biomedicine · MLC-T-ONC-004340

A drug used to treat adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is also being studied in the treatment of other conditions. Inrebic blocks JAK2 and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called fedratinib hydrochloride.

Table 1. Record
IdentifierMLC-T-ONC-004340
FieldOncology and biomedicine
Synonymsfedratinib hydrochloride
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004340",
  "term": "Inrebic",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is also being studied in the treatment of other conditions. Inrebic blocks JAK2 and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called fedratinib hydrochloride.",
  "synonyms": [
    "fedratinib hydrochloride"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/inrebic/"
}

Record 9,294 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.